Completed NA INTERVENTIONAL 1-arm NCT01857947

Prognosis Value of Pro-adrenomedullin in Acute Exacerbations of COPD in ER (UTAPE BPCO)

Usefulness of Pro-adrenomedullin (MR proADM)as a Predictor of Outcome in Acute Exacerbations of COPD Visiting the Emergency Room

Sponsor: Assistance Publique - Hôpitaux de Paris

Conditions Pulmonary Disease, Chronic Obstructive Patients Admitted in Emergency Department for Acute Exacerbation

Interventions AECOPD Mr proADM

Updated 5 times since 2017 Last updated: Dec 2, 2014 Started: Mar 31, 2013 Primary completion: Oct 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01857947, this NA trial focuses on Pulmonary Disease, Chronic Obstructive Patients Admitted in Emergency Department for Acute Exacerbation and remains completed. Sponsored by Assistance Publique - Hôpitaux de Paris, it has been updated 5 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assistance Publique - Hôpitaux de Paris
ThermoFisher Scientific Brahms Biomarkers France

Data source: ThermoFisher Scientific Brahms Biomarkers France

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France